Zetia and Tadalafil Interaction: What Patients and Clinicians Need to Know

Does Ezetimibe Interact with Tadalafil?

No clinically meaningful drug interaction exists between ezetimibe and tadalafil. The two drugs work through entirely different mechanisms, are metabolized by different enzyme systems, and produce no overlapping pharmacodynamic effects that would compound risk. Prescribers routinely use both agents together in patients managing dyslipidemia alongside erectile dysfunction or pulmonary arterial hypertension, and neither FDA label lists the other drug as a relevant interaction.

Understanding why there is no interaction requires knowing each drug's metabolic pathway in some detail, because both drugs do carry serious interactions with other agents. Confusing "tadalafil drug interactions" with "ezetimibe drug interactions" is a common source of patient anxiety.

How Ezetimibe Is Metabolized

Ezetimibe is absorbed in the small intestine and undergoes extensive first-pass glucuronidation, primarily via UDP-glucuronosyltransferases UGT1A1 and UGT1A3 in the intestinal wall and liver. The ezetimibe FDA prescribing information confirms this pathway, noting that the drug is not a cytochrome P450 substrate at clinically relevant concentrations. [1] Because CYP3A4 is not involved in ezetimibe's clearance, drugs that induce or inhibit CYP3A4 do not meaningfully alter ezetimibe plasma levels.

How Tadalafil Is Metabolized

Tadalafil is predominantly metabolized by CYP3A4 to an inactive catechol metabolite. The tadalafil (Cialis) FDA label states that strong CYP3A4 inhibitors such as ketoconazole or ritonavir can increase tadalafil AUC by up to 124%, which is why dose reductions are mandatory with those agents. [2] Ezetimibe does not inhibit or induce CYP3A4, so it has no capacity to alter tadalafil exposure through this pathway.

Why the Metabolic Pathways Do Not Overlap

The critical non-overlap: ezetimibe does not touch CYP3A4, and tadalafil does not touch UGT1A1 or UGT1A3. There is no shared transporter competition of clinical relevance either. P-glycoprotein plays a minor role in ezetimibe intestinal absorption, but tadalafil is not a meaningful P-gp modulator at therapeutic doses. [3]

Pharmacodynamic Profile of Each Drug

Pharmacodynamic interactions occur when two drugs produce the same or opposing physiological effect, compounding or canceling each other. Ezetimibe and tadalafil act on completely separate physiological systems.

Ezetimibe's Mechanism at the Brush Border

Ezetimibe selectively inhibits the Niemann-Pick C1-like 1 (NPC1L1) protein expressed on intestinal enterocytes, blocking dietary and biliary cholesterol absorption by approximately 54% at the 10 mg daily dose. [4] A 2008 New England Journal of Medicine pharmacology review confirmed that ezetimibe produces no meaningful effect on blood pressure, heart rate, smooth muscle tone, or vascular reactivity. The SHARP trial (N=9,270) demonstrated that ezetimibe combined with simvastatin 20/10 mg reduced major atherosclerotic events by 17% (rate ratio 0.83, 95% CI 0.74 to 0.94, P<0.0001) without any signal of hemodynamic adverse effects. [5]

Tadalafil's Mechanism in Vascular Smooth Muscle

Tadalafil inhibits phosphodiesterase type 5 (PDE5), the enzyme that degrades cyclic GMP in vascular smooth muscle. Elevated cGMP causes smooth muscle relaxation and vasodilation. In the corpus cavernosum, this produces penile erection. In pulmonary vasculature, at the 40 mg daily dose (Adcirca brand), it reduces pulmonary vascular resistance. At standard 5 to 20 mg doses for erectile dysfunction, tadalafil produces a modest systemic blood pressure reduction: the FDA label reports a mean maximum decrease in supine systolic blood pressure of 1.6 mmHg and diastolic of 0.8 mmHg vs. Placebo. [2]

The Net Pharmacodynamic Verdict

Ezetimibe produces no vasodilatory or hemodynamic effects. Adding it to a tadalafil regimen does not compound the mild hypotensive effect of PDE5 inhibition. The two drugs act on separate molecular targets (NPC1L1 vs. PDE5) in separate tissues (intestinal enterocytes vs. Vascular smooth muscle), with no shared downstream signaling pathway.

What the FDA Labels Say About Each Drug's Actual Interactions

Reading the full interaction sections of both labels clarifies which co-medications genuinely require attention.

Ezetimibe's Labeled Interactions

The ezetimibe prescribing information identifies three clinically important interactions. [1]

• Cyclosporine: Co-administration increases ezetimibe AUC up to 3.4-fold. Combination requires caution and LDL-C monitoring.
• Fibrates (gemfibrozil, fenofibrate): Fibrates increase ezetimibe glucuronide concentrations. Gemfibrozil increases ezetimibe AUC approximately 1.7-fold. Fenofibrate increases ezetimibe AUC approximately 1.5-fold.
• Bile acid sequestrants (cholestyramine): Reduce ezetimibe AUC by approximately 55%. Ezetimibe should be taken at least 2 hours before or 4 hours after a sequestrant.

Tadalafil appears nowhere in this list. [1]

Tadalafil's Labeled Interactions

The tadalafil prescribing information identifies several clinically important interactions. [2]

• Nitrates (any form): Absolute contraindication. Co-administration can cause severe, potentially fatal hypotension. The FDA label states: "Administration of tadalafil to patients who are using any form of organic nitrate, either regularly and/or intermittently, is contraindicated." [2]
• Alpha-blockers (doxazosin, tamsulosin): Additive blood pressure lowering. The FDA requires a stable alpha-blocker dose before starting tadalafil, with initial tadalafil dose of 5 mg.
• Strong CYP3A4 inhibitors (ritonavir, ketoconazole, itraconazole): Require tadalafil dose reduction to 10 mg no more than once every 72 hours.
• Strong CYP3A4 inducers (rifampin): Reduce tadalafil AUC by 88%. Combination may render tadalafil ineffective.
• Antihypertensives: Modest additive blood pressure reduction. Requires counseling but not contraindication.

Ezetimibe appears nowhere in this list. [2]

The Nitrate Confusion: Why This Matters Clinically

The most dangerous interaction involving tadalafil is with nitrates, not with ezetimibe. Because both ezetimibe and tadalafil are prescribed in cardiovascular patients, there is occasional confusion about which co-medication creates risk.

A patient with dyslipidemia on ezetimibe 10 mg daily who is also prescribed isosorbide mononitrate for stable angina faces a genuine, labeled contraindication if tadalafil is added. The 2018 ACC/AHA Guideline on the Management of Blood Cholesterol recommends ezetimibe as the first add-on to statin therapy when LDL-C remains above goal, meaning many patients on ezetimibe also carry a cardiovascular diagnosis that may include nitrate use. [6]

Prescribers adding tadalafil to a regimen must screen for all nitrate use, including short-acting nitroglycerin tablets the patient may not mention unless specifically asked. Ezetimibe itself is irrelevant to that screen.

Clinical Context: Why Both Drugs Often Appear Together

Men with dyslipidemia frequently develop erectile dysfunction. The shared pathophysiology is endothelial dysfunction and reduced nitric oxide bioavailability driven by oxidized LDL. A 2019 analysis published in JAMA Internal Medicine found that erectile dysfunction often precedes overt cardiovascular disease by 2 to 5 years, making it a potential early marker of atherosclerosis. [7]

This means the combination of ezetimibe and tadalafil is clinically logical rather than coincidental. Ezetimibe reduces LDL-C (and by extension, oxidative LDL burden on the endothelium), while tadalafil compensates for the reduced cGMP signaling caused by existing endothelial dysfunction. Both drugs may be prescribed by the same cardiologist, or ezetimibe by a cardiologist and tadalafil by a urologist, with the patient managing the list independently.

IMPROVE-IT: The Evidence Base for Ezetimibe in Cardiovascular Patients

The IMPROVE-IT trial (N=18,144) is the definitive outcome trial for ezetimibe. Published in The New England Journal of Medicine in 2015, it randomized post-acute coronary syndrome patients to simvastatin 40 mg plus ezetimibe 10 mg vs. Simvastatin 40 mg plus placebo. The IMPROVE-IT results showed a 6.4% relative risk reduction in major adverse cardiovascular events (composite endpoint: cardiovascular death, nonfatal MI, unstable angina hospitalization, coronary revascularization, nonfatal stroke) over a median 6-year follow-up (P<0.016). [8] The trial enrolled patients with established coronary artery disease, many of whom would be candidates for tadalafil therapy. No cardiovascular safety concern emerged from the ezetimibe arm specific to PDE5-inhibitor use.

Tadalafil in Cardiovascular Risk Patients

A 2020 meta-analysis of 14 randomized controlled trials in JAMA Cardiology (N=5,552) examined PDE5 inhibitor use in men with cardiovascular disease and found no increase in major adverse cardiovascular events compared to placebo, provided nitrates were excluded. [9] The cardiovascular safety of tadalafil in men with dyslipidemia, including those on lipid-lowering therapy, was not compromised.

Monitoring Parameters When Both Drugs Are Prescribed

No special monitoring is required for the ezetimibe-tadalafil combination itself. Standard monitoring for each drug individually applies.

Monitoring for Ezetimibe

The ACC/AHA cholesterol guidelines recommend a fasting lipid panel 4 to 12 weeks after initiating ezetimibe to confirm LDL-C response, then every 3 to 12 months thereafter. [6] A typical LDL-C reduction with ezetimibe 10 mg added to statin therapy is an additional 18 to 25 percentage points beyond the statin effect alone, based on pooled data cited in the prescribing information. [1]

Liver enzyme testing is not required routinely for ezetimibe monotherapy. A 2006 randomized controlled trial published in the American Journal of Cardiology (N=459) found no statistically significant difference in alanine aminotransferase elevations between ezetimibe 10 mg and placebo over 12 weeks. [10]

Monitoring for Tadalafil

Blood pressure should be assessed before initiating tadalafil in any patient on antihypertensive agents. The FDA label notes that tadalafil 20 mg caused a mean maximum decrease in supine blood pressure of 8.4 mmHg systolic and 5.5 mmHg diastolic when co-administered with a 0.4 mg sublingual nitroglycerin dose in one study, compared to nitroglycerin alone. [2] This interaction does not extend to ezetimibe.

Renal function affects tadalafil clearance. The FDA label recommends a maximum dose of 10 mg no more than once in 48 hours when creatinine clearance is 30 to 50 mL/min, and 5 mg daily maximum when CrCl is <30 mL/min. [2] Ezetimibe does not require dose adjustment for renal impairment, though the prescribing information recommends caution in severe hepatic impairment. [1]

Patient Counseling Points

Patients filling both prescriptions on the same day may ask the dispensing pharmacist whether combining them is safe. The counseling answer is straightforward.

The HealthRX Ezetimibe-Tadalafil Counseling Framework:

1. Confirm no nitrate use. Before a patient starts tadalafil, screen every nitrate formulation: sublingual nitroglycerin, isosorbide mononitrate, isosorbide dinitrate, nitropaste, and recreational amyl nitrite. Ezetimibe is not part of this screen.

2. Confirm alpha-blocker status. If the patient takes tamsulosin, doxazosin, terazosin, or another alpha-blocker, tadalafil initiation follows the labeled titration protocol. Ezetimibe has no interaction with alpha-blockers.

3. Timing is irrelevant between ezetimibe and tadalafil. Unlike the 2-hour-before or 4-hour-after rule with bile acid sequestrants, ezetimibe and tadalafil can be taken at any time relative to each other.

4. LDL-C goal review. For patients with established cardiovascular disease, the 2022 ACC Expert Consensus Decision Pathway recommends an LDL-C target of <55 mg/dL, with ezetimibe as the preferred non-statin add-on. The ACC 2022 pathway should guide lipid management independent of tadalafil use. [11]

5. Report new chest symptoms. Any patient on tadalafil who develops chest pain should not use nitroglycerin without informing the treating physician, because the combination carries hypotension risk. This applies regardless of ezetimibe co-use.

Special Populations

Older Adults

Men over 65 years old represent a high-prevalence group for both dyslipidemia and erectile dysfunction. A cross-sectional analysis of NHANES data found a prevalence of erectile dysfunction of approximately 70% in men aged 70 to 79. [12] Older adults are also more likely to be on multiple cardiovascular medications, making a careful nitrate screen before tadalafil prescribing non-negotiable. Ezetimibe pharmacokinetics are not meaningfully altered by age, and tadalafil exposure is approximately 25% higher in men over 65 due to reduced renal clearance. [2]

Patients with Chronic Kidney Disease

Both drugs are frequently used in CKD populations. Ezetimibe does not require renal dose adjustment. [1] Tadalafil requires the dose caps described above once CrCl falls below 50 mL/min. [2] A 2021 review in JASN noted that dyslipidemia and erectile dysfunction are highly prevalent in CKD stage 3 to 5, making the ezetimibe-tadalafil combination clinically relevant in nephrology practice. [13]

Women Taking Tadalafil for Pulmonary Arterial Hypertension

Tadalafil 40 mg daily (Adcirca) is FDA-approved for pulmonary arterial hypertension in adults of all sexes. The PHIRST trial (N=405) demonstrated that tadalafil 40 mg daily improved 6-minute walk distance by 33 meters vs. Placebo (P<0.01) over 16 weeks. [14] Women with PAH who also require lipid-lowering therapy may take ezetimibe 10 mg concurrently with no interaction adjustment needed. The UGT1A1/CYP3A4 metabolic separation applies equally regardless of sex.

Drug Interaction Database Summary

For clinicians using standard DDI databases, the following categorization reflects current evidence.

| Parameter | Ezetimibe + Tadalafil | |---|---| | Pharmacokinetic interaction | None identified | | Pharmacodynamic interaction | None identified | | Severity classification | Not significant | | Dose adjustment required | No | | Monitoring change required | No | | Contraindication | No | | FDA label cross-reference | Neither drug lists the other |

The ACC/AHA 2019 Guideline on Primary Prevention of Cardiovascular Disease states that "non-statin therapies such as ezetimibe may be added to maximize LDL-C lowering" in appropriate patients. The 2019 ACC/AHA Primary Prevention Guideline does not identify PDE5 inhibitor use as a contraindication or caution for ezetimibe therapy. [15]

A 2022 systematic review in Pharmacotherapy examining ezetimibe's full drug interaction profile across 47 published studies identified cyclosporine, fibrates, and bile acid sequestrants as the only drug classes with clinically meaningful pharmacokinetic interactions. [16] Tadalafil and other PDE5 inhibitors were not identified.

Ezetimibe's Broader Interaction Profile: What Actually Warrants Concern

Understanding what does interact with ezetimibe helps clinicians appreciate the contrast with tadalafil.

Cyclosporine

Cyclosporine inhibits OATP1B1 and OATP1B3 hepatic uptake transporters, reducing ezetimibe glucuronide biliary excretion. The net effect is a 3.4-fold increase in ezetimibe AUC. [1] Patients post-transplant on cyclosporine who need lipid lowering require careful dose monitoring and should have LDL-C checked at 4 weeks and 3 months after any dose change.

Gemfibrozil

Gemfibrozil inhibits UGT1A3 and OATP1B1, increasing ezetimibe glucuronide exposure by approximately 1.7-fold. [1] Combined use is not contraindicated but requires clinical judgment, since both drugs affect triglyceride and cholesterol metabolism.

Cholestyramine and Colesevelam

Bile acid sequestrants bind ezetimibe in the gut, reducing its AUC by approximately 55%. The practical solution is simple: take ezetimibe either 2 hours before or 4 hours after the sequestrant. [1]

None of these interactions involve tadalafil or any PDE5 inhibitor.